<?xml version="1.0" encoding="iso-8859-1"?>
<rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/">
	<channel>
		
		<title>Euro Biotech News</title>
		<link>http://www.eurobiotechnews.eu/</link>
		<description>Life Sciences</description>
		<language>en</language>
		<image>
			<title>Euro Biotech News</title>
			<url>http://www.eurobiotechnews.eu/EXT:tt_news/ext_icon.gif</url>
			<link>http://www.eurobiotechnews.eu/</link>
			<width>144</width>
			<height>73</height>
			<description>Life Sciences</description>
		</image>
		<generator>TYPO3 - get.content.right</generator>
		<docs>http://blogs.law.harvard.edu/tech/rss</docs>
		<copyright>BIOCOM AG, Germany 2005-2009</copyright>
		
		
		<lastBuildDate>Fri, 03 Feb 2012 04:29:55 +0100</lastBuildDate>
		
		
		<item>
			<title>AstraZeneca sheds thousands of jobs</title>
			<link>http://www.eurobiotechnews.eu/index.php?id=11535&#38;no_cache=1&#38;tx_ttnews%5Btt_news%5D=14068&#38;cHash=cc0f5002a3</link>
			<description>London - AstraZeneca tries to shed some weight, anticipating a tough year   ahead. 7,300 jobs will be gone soon, the...</description>
			<content:encoded><![CDATA[London - AstraZeneca tries to shed some weight, anticipating a tough year   ahead. 7,300 jobs will be gone soon, the Anglo-Swedish drug company   said in a statement. Research and...]]></content:encoded>
			<category>UK</category>
			
			
			<pubDate>Fri, 03 Feb 2012 04:29:55 +0100</pubDate>
			
		</item>
		
		<item>
			<title>No allergy against the stock market</title>
			<link>http://www.eurobiotechnews.eu/index.php?id=11535&#38;no_cache=1&#38;tx_ttnews%5Btt_news%5D=14065&#38;cHash=d5d13bc61c</link>
			<description>Bagneux - DBV Technologies is planning an IPO on Euronext Paris. The French pharmaceutical group specialising in the...</description>
			<content:encoded><![CDATA[Bagneux - DBV Technologies is planning an IPO on Euronext Paris. The French pharmaceutical group specialising in the treatment of allergies was founded in 2002. DBV's proprietary...]]></content:encoded>
			<category>France</category>
			
			
			<pubDate>Thu, 02 Feb 2012 04:18:52 +0100</pubDate>
			
		</item>
		
		<item>
			<title>An ocean of fuels</title>
			<link>http://www.eurobiotechnews.eu/index.php?id=11535&#38;no_cache=1&#38;tx_ttnews%5Btt_news%5D=14063&#38;cHash=5af9125216</link>
			<description>Copenhagen/Bangalore  Biofuels need reliable sources of biomass.  Novozymes now looks to the ocean to secure biomass....</description>
			<content:encoded><![CDATA[Copenhagen/Bangalore &#8211; Biofuels need reliable sources of biomass.  <br />Novozymes now looks to the ocean to secure biomass. The Danish enzyme specialist announced an exploratory...]]></content:encoded>
			<category>Denmark</category>
			
			
			<pubDate>Wed, 01 Feb 2012 04:46:33 +0100</pubDate>
			
		</item>
		
		<item>
			<title>Actavis and Bioton set out to conquer diabetes market</title>
			<link>http://www.eurobiotechnews.eu/index.php?id=11535&#38;no_cache=1&#38;tx_ttnews%5Btt_news%5D=14061&#38;cHash=ef38d1360c</link>
			<description>Zug/Warsaw - The fourth largest generics producer and a polish biotech want to create a stir in the market for diabetes...</description>
			<content:encoded><![CDATA[Zug/Warsaw - The fourth largest generics producer and a polish biotech want to create a stir in the market for diabetes drugs. Swiss Actavis and Bioton from Warsaw announced that...]]></content:encoded>
			<category>Poland</category>
			
			
			<pubDate>Tue, 31 Jan 2012 06:22:16 +0100</pubDate>
			
		</item>
		
		<item>
			<title>Common guidelines for feed and food from GMOs</title>
			<link>http://www.eurobiotechnews.eu/index.php?id=11535&#38;no_cache=1&#38;tx_ttnews%5Btt_news%5D=14060&#38;cHash=824bde30fa</link>
			<description>Brussels - The unification process in Europe is in full swing - at least in genetics. The European Commission and the...</description>
			<content:encoded><![CDATA[Brussels - The unification process in Europe is in full swing - at least in genetics. The European Commission and the European Food Safety Authority (EFSA) have both published...]]></content:encoded>
			
			
			<pubDate>Mon, 30 Jan 2012 06:46:00 +0100</pubDate>
			
		</item>
		
		<item>
			<title>Amgen to Buy Micromet </title>
			<link>http://www.eurobiotechnews.eu/index.php?id=11535&#38;no_cache=1&#38;tx_ttnews%5Btt_news%5D=14058&#38;cHash=02f1dc63c2</link>
			<description>Thousand Oaks/Munich - Bling bling for blinatumomab. It is a compliment for the European life sciences scene and sad...</description>
			<content:encoded><![CDATA[Thousand Oaks/Munich - Bling bling for blinatumomab. It is a compliment for the European life sciences scene and sad news at the same time. Amgen Inc., the world's largest...]]></content:encoded>
			
			
			<pubDate>Fri, 27 Jan 2012 05:26:00 +0100</pubDate>
			
		</item>
		
		<item>
			<title>Roche makes a US-$5.7bn hostile bid for Illumina</title>
			<link>http://www.eurobiotechnews.eu/index.php?id=11535&#38;no_cache=1&#38;tx_ttnews%5Btt_news%5D=14055&#38;cHash=64578a1f73</link>
			<description>Basel  The rumours started just before Christmas. Roche wants Illumina. Just how dearly, has just become clear. The...</description>
			<content:encoded><![CDATA[Basel &#8211; The rumours started just before Christmas. Roche wants Illumina. Just how dearly, has just become clear. The Swiss drugmaker made a $5.7b hostile bid for Illumina, the...]]></content:encoded>
			<category>Switzerland</category>
			
			
			<pubDate>Thu, 26 Jan 2012 04:41:25 +0100</pubDate>
			
		</item>
		
		<item>
			<title>DSM in $250m cellulosic ethanol joint venture</title>
			<link>http://www.eurobiotechnews.eu/index.php?id=11535&#38;no_cache=1&#38;tx_ttnews%5Btt_news%5D=14053&#38;cHash=6e859ea26a</link>
			<description>Amsterdam  Two elephants in the biofuels business join forces. Dutch food and chemicals group Royal DSM and POET, LLC,...</description>
			<content:encoded><![CDATA[Amsterdam &#8211; Two elephants in the biofuels business join forces. Dutch food and chemicals group Royal DSM and POET, LLC, a US-based ethanol producer, announced a plan to build a...]]></content:encoded>
			<category>BeNeLux</category>
			
			
			<pubDate>Wed, 25 Jan 2012 04:06:06 +0100</pubDate>
			
		</item>
		
		<item>
			<title>Label change for Elan's MS-drug permits safer use</title>
			<link>http://www.eurobiotechnews.eu/index.php?id=11535&#38;no_cache=1&#38;tx_ttnews%5Btt_news%5D=14046&#38;cHash=43966faada</link>
			<description>Weston/Dublin - The focus for Tysabri, the MS drug jointly developed by Irish Elan and US-Biogen, has become a little...</description>
			<content:encoded><![CDATA[Weston/Dublin - The focus for Tysabri, the MS drug jointly developed by Irish Elan and US-Biogen, has become a little more accurate. The US Food and Drug Administration (FDA)...]]></content:encoded>
			<category>Ireland</category>
			
			
			<pubDate>Tue, 24 Jan 2012 04:53:20 +0100</pubDate>
			
		</item>
		
		<item>
			<title>Novartis loves and fears EMA</title>
			<link>http://www.eurobiotechnews.eu/index.php?id=11535&#38;no_cache=1&#38;tx_ttnews%5Btt_news%5D=14044&#38;cHash=406572d554</link>
			<description>Basel  Good and bad news for Swiss drugmaker Novartis. First a look on the bright side: Signifor, for the treatment of...</description>
			<content:encoded><![CDATA[Basel &#8211; Good and bad news for Swiss drugmaker Novartis. First a look on the bright side: Signifor, for the treatment of Cushing's disease, is on its final stretch to approval. The...]]></content:encoded>
			<category>Switzerland</category>
			
			
			<pubDate>Mon, 23 Jan 2012 04:28:43 +0100</pubDate>
			
		</item>
		
		<item>
			<title>4SC gets a confidence boost in clinic and stockmarket</title>
			<link>http://www.eurobiotechnews.eu/index.php?id=11535&#38;no_cache=1&#38;tx_ttnews%5Btt_news%5D=14042&#38;cHash=d103e26ed8</link>
			<description>Martinsried - SHELTER is responsible for the fact that the stocks of 4SC behaved like a rodeo horse on Thursday. The...</description>
			<content:encoded><![CDATA[Martinsried - SHELTER is responsible for the fact that the stocks of 4SC behaved like a rodeo horse on Thursday. The shares rose in several stages up to 63%, only to settle at a...]]></content:encoded>
			<category>Germany</category>
			
			
			<pubDate>Fri, 20 Jan 2012 06:58:33 +0100</pubDate>
			
		</item>
		
		<item>
			<title>Clavis Pharma gets 21m for anti-cancer pipeline</title>
			<link>http://www.eurobiotechnews.eu/index.php?id=11535&#38;no_cache=1&#38;tx_ttnews%5Btt_news%5D=14040&#38;cHash=a2c76dd035</link>
			<description>Oslo  The north lights up with financial flares. Norwegian cancer specialist Clavis Pharma ASA has raised 21m through...</description>
			<content:encoded><![CDATA[Oslo &#8211; The north lights up with financial flares. Norwegian cancer specialist Clavis Pharma ASA has raised &#8364;21m through a placement of new shares. The 2.8 million shares represent...]]></content:encoded>
			<category>Norway</category>
			
			
			<pubDate>Thu, 19 Jan 2012 04:19:00 +0100</pubDate>
			
		</item>
		
		<item>
			<title>Biotechs emerge as important players in 2012</title>
			<link>http://www.eurobiotechnews.eu/index.php?id=11535&#38;no_cache=1&#38;tx_ttnews%5Btt_news%5D=14038&#38;cHash=ca97745843</link>
			<description>Brussels  Predicting the future is often not more than a guessing game. But two signs recently appeared on the horizon...</description>
			<content:encoded><![CDATA[Brussels &#8211; Predicting the future is often not more than a guessing game. But two signs recently appeared on the horizon which indicate that the biotechnology industry will play a...]]></content:encoded>
			<category>Politics / Law</category>
			
			
			<pubDate>Wed, 18 Jan 2012 04:52:08 +0100</pubDate>
			
		</item>
		
		<item>
			<title>BASF Plant Science says goodbye to Europe</title>
			<link>http://www.eurobiotechnews.eu/index.php?id=11535&#38;no_cache=1&#38;tx_ttnews%5Btt_news%5D=14036&#38;cHash=f55a7c87d0</link>
			<description>Ludwigshafen  BASF Plant Science GmbH, the agrochemistry and biotech arm of the world-largest chemistry company,...</description>
			<content:encoded><![CDATA[Ludwigshafen &#8211; BASF Plant Science GmbH, the agrochemistry and biotech arm of the world-largest chemistry company, thinks that it has outstayed its welcome in Europe. Over the next...]]></content:encoded>
			<category>Germany</category>
			
			
			<pubDate>Tue, 17 Jan 2012 05:14:50 +0100</pubDate>
			
		</item>
		
		<item>
			<title>New biotech park in Scotland</title>
			<link>http://www.eurobiotechnews.eu/index.php?id=11535&#38;no_cache=1&#38;tx_ttnews%5Btt_news%5D=14034&#38;cHash=5bb0e50eaa</link>
			<description>Newhouse  An example of Schumpeter's dictum of creative destruction can be witnessed in Scotland. A former research...</description>
			<content:encoded><![CDATA[Newhouse &#8211; An example of Schumpeter's dictum of creative destruction can be witnessed in Scotland. A former research site of US-pharma company Merck will be reborn as a biotech...]]></content:encoded>
			<category>UK</category>
			
			
			<pubDate>Mon, 16 Jan 2012 06:12:51 +0100</pubDate>
			
		</item>
		
		<item>
			<title>Dutch DSM joins an EU consortium to battle ocular diseases</title>
			<link>http://www.eurobiotechnews.eu/index.php?id=11535&#38;no_cache=1&#38;tx_ttnews%5Btt_news%5D=14032&#38;cHash=92b1faaf20</link>
			<description>Heerlen - Royal DSM N.V will be the industrial partner to the Panoptes consortium, which aims to develop novel drug...</description>
			<content:encoded><![CDATA[Heerlen - Royal DSM N.V will be the industrial partner to the Panoptes consortium, which aims to develop novel drug delivery technology for the posterior eye segment. The four...]]></content:encoded>
			<category>BeNeLux</category>
			
			
			<pubDate>Fri, 13 Jan 2012 08:33:50 +0100</pubDate>
			
		</item>
		
		<item>
			<title>Organobalance sells yeast strain to Sanofi</title>
			<link>http://www.eurobiotechnews.eu/index.php?id=11535&#38;no_cache=1&#38;tx_ttnews%5Btt_news%5D=14026&#38;cHash=c6363fb6e1</link>
			<description>Berlin/Paris  Sanofi Pasteur has licensed a yeast strain from German Organobalance to produce vaccines. With the deal,...</description>
			<content:encoded><![CDATA[Berlin/Paris &#8211; Sanofi Pasteur has licensed a yeast strain from German Organobalance to produce vaccines. With the deal, the vaccines division of the French drugmaker will gain...]]></content:encoded>
			<category>France</category>
			
			
			<pubDate>Thu, 12 Jan 2012 06:05:02 +0100</pubDate>
			
		</item>
		
		<item>
			<title>Norwegian BergenBio gets Series A financing for cancer candidate</title>
			<link>http://www.eurobiotechnews.eu/index.php?id=11535&#38;no_cache=1&#38;tx_ttnews%5Btt_news%5D=14024&#38;cHash=65a32e1cfb</link>
			<description>Bergen  BerGenBio A/S announced it has completed an 6.9m Series A financing round. The money will be spent in taking...</description>
			<content:encoded><![CDATA[Bergen &#8211; BerGenBio A/S announced it has completed an &#8364;6.9m Series A financing round. The money will be spent in taking their lead compound BGB324 into clinical trials and to...]]></content:encoded>
			<category>Norway</category>
			
			
			<pubDate>Wed, 11 Jan 2012 04:59:20 +0100</pubDate>
			
		</item>
		
		<item>
			<title>National Cancer Institute supports Micromet</title>
			<link>http://www.eurobiotechnews.eu/index.php?id=11535&#38;no_cache=1&#38;tx_ttnews%5Btt_news%5D=14017&#38;cHash=8c64d50a04</link>
			<description>Munich - It is the accolade for Micromet. The German company, which is listed on the U.S. stock exchange, announced...</description>
			<content:encoded><![CDATA[Munich - It is the accolade for Micromet. The German company, which is listed on the U.S. stock exchange, announced today that it has entered into a Cooperative Research and...]]></content:encoded>
			<category>Germany</category>
			
			
			<pubDate>Tue, 10 Jan 2012 07:26:26 +0100</pubDate>
			
		</item>
		
		<item>
			<title>Chimp viruses as a vector for human vaccines</title>
			<link>http://www.eurobiotechnews.eu/index.php?id=11535&#38;no_cache=1&#38;tx_ttnews%5Btt_news%5D=14015&#38;cHash=ba8a5a7cb5</link>
			<description>Rome  A cold virus isolated from chimpanzees might work as an vector for human vaccines. Adenoviruses are principally...</description>
			<content:encoded><![CDATA[Rome &#8211; A cold virus isolated from chimpanzees might work as an vector for human vaccines. Adenoviruses are principally suitable as vectors for vaccines for their ability to induce...]]></content:encoded>
			<category>Italy</category>
			
			
			<pubDate>Mon, 09 Jan 2012 06:20:20 +0100</pubDate>
			
		</item>
		
		<item>
			<title>Boehringer Ingelheim ready to pay 65m for Forma's cancer services</title>
			<link>http://www.eurobiotechnews.eu/index.php?id=11535&#38;no_cache=1&#38;tx_ttnews%5Btt_news%5D=14013&#38;cHash=aa9e8090e2</link>
			<description>Ingelheim/Watertown  Boehringer Ingelheim seems to be very impressed by the ability of a small US-biotech to find and...</description>
			<content:encoded><![CDATA[Ingelheim/Watertown &#8211; Boehringer Ingelheim seems to be very impressed by the ability of a small US-biotech to find and develop cancer drug candidates. The Germans have agreed to...]]></content:encoded>
			<category>Germany</category>
			
			
			<pubDate>Fri, 06 Jan 2012 07:05:17 +0100</pubDate>
			
		</item>
		
		<item>
			<title>Servier engages BioInvent for cancer antibody</title>
			<link>http://www.eurobiotechnews.eu/index.php?id=11535&#38;no_cache=1&#38;tx_ttnews%5Btt_news%5D=14011&#38;cHash=770e2e4599</link>
			<description>Stockholm/Suresnes - Swedish BioInvent International AB and French Laboratoires Servier are working together on an...</description>
			<content:encoded><![CDATA[Stockholm/Suresnes - Swedish BioInvent International AB and French Laboratoires Servier are working together on an oncology target. Under the terms of the agreement, Servier will...]]></content:encoded>
			<category>France</category>
			
			
			<pubDate>Thu, 05 Jan 2012 05:06:47 +0100</pubDate>
			
		</item>
		
		<item>
			<title>Pharming announces 8.4 million convertible bond financing</title>
			<link>http://www.eurobiotechnews.eu/index.php?id=11535&#38;no_cache=1&#38;tx_ttnews%5Btt_news%5D=14009&#38;cHash=0e34be7929</link>
			<description>Leiden - Dutch Pharming Group NV has taken a further step to secure sound financing even beyond the recent milestone...</description>
			<content:encoded><![CDATA[Leiden - Dutch Pharming Group NV has taken a further step to secure sound financing even beyond the recent milestone payments. The drug developer announced that it has entered...]]></content:encoded>
			<category>BeNeLux</category>
			
			
			<pubDate>Wed, 04 Jan 2012 07:41:29 +0100</pubDate>
			
		</item>
		
		<item>
			<title>Consortium of seven European countries tackles multiple myeloma</title>
			<link>http://www.eurobiotechnews.eu/index.php?id=11535&#38;no_cache=1&#38;tx_ttnews%5Btt_news%5D=14007&#38;cHash=a4cba34a66</link>
			<description>Innsbruck/Brussels - Twelve institutions in seven countries are working together to learn more about how one of the...</description>
			<content:encoded><![CDATA[Innsbruck/Brussels - Twelve institutions in seven countries are working together to learn more about how one of the deadliest cancers interacts with its environment. The...]]></content:encoded>
			<category>BioFunding</category>
			
			
			<pubDate>Tue, 03 Jan 2012 06:03:42 +0100</pubDate>
			
		</item>
		
		<item>
			<title>Zealand Pharma announces positive safety data</title>
			<link>http://www.eurobiotechnews.eu/index.php?id=11535&#38;no_cache=1&#38;tx_ttnews%5Btt_news%5D=13938&#38;cHash=fb68e4ceb8</link>
			<description>Copenhagen  Hellsinn Healthcare has successfully completed a phase Ib trial in Europe with Zealand Pharmas GLP-2...</description>
			<content:encoded><![CDATA[Copenhagen &#8211; Hellsinn Healthcare has successfully completed a phase Ib trial in Europe with Zealand Pharma&#8217;s GLP-2 (glucagone-like peptide 2) peptide antagonist Elsiglutide...]]></content:encoded>
			<category>Denmark</category>
			
			
			<pubDate>Mon, 02 Jan 2012 05:26:38 +0100</pubDate>
			
		</item>
		
	</channel>
</rss>
